<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069302</url>
  </required_header>
  <id_info>
    <org_study_id>C369</org_study_id>
    <nct_id>NCT01069302</nct_id>
  </id_info>
  <brief_title>Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of high dose clopidogrel as the
      antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for
      percutaneous coronary intervention due to ischemic heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy of aspirin and thienopyridine is used to prevent stent thrombosis
      after percutaneous coronary intervention (PCI). Clopidogrel is the most popular
      thienopyridine. Following the 300mg clopidogrel loading dose (LD) at first day, patients take
      75mg maintenance dose (MD) to inhibit platelet aggregation after coronary stent implantation.
      600mg high LD inhibit platelet aggregation more rapidly and strongly than standard LD and
      prevent thrombotic event around the PCI. Similarly high MD inhibit platelet aggregation more
      strongly. Interindividual variability of clopidogrel anti-platelet effect has been reported.
      In Japanese, there are many non or hyporesponders to clopidogrel compared to the Western
      population. The purpose of this study is to evaluate the effect of high dose clopidogrel as
      the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled
      for PCI due to ischemic heart disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation 24 hours after loading</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet aggregation 7 days after loading</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet aggregation 28 days after loading</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis (Academic Research Consortium definition)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute hemorrhagic or ischemic stroke excluding transient ischemic attack</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications (Global Use of Strategies to Open Occluded Coronary Arteries [GUSTO] and Thrombolysis In Myocardial Infarction [TIMI] definition)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of cardiac death, myocardial infarction and stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>High loading and high maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel loading 600mg and maintenance 150mg for 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High loading and low maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel loading 600mg and maintenance 75mg for 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low loading and high maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel loading 300mg and maintenance 150mg for 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low loading and low maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel loading 300mg and maintenance 75mg for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel loading 600mg and maintenance 150mg for 7days</description>
    <arm_group_label>High loading and high maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel loading 600mg and maintenance 75mg for 7days</description>
    <arm_group_label>High loading and low maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel loading 300mg and maintenance 150mg for 7days</description>
    <arm_group_label>Low loading and high maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel loading 300mg and maintenance 75mg for 7days</description>
    <arm_group_label>Low loading and low maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for percutaneous coronary intervention due to ischemic heart
             disease

          -  Patients taking aspirin 81-100mg at least 1 week.

        Exclusion Criteria:

          -  Patients with ST elevation myocardial infarction

          -  Patients have contraindication of aspirin or clopidogrel

          -  Patients taking warfarin

          -  Patients received thrombolytic therapy within 2 weeks

          -  Patients taking anti-platelet agents except aspirin within 1 month

          -  Patients taking corticosteroid.

          -  Patients taking proton pump inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

